Is IDEXX Laboratories Stock a Good Investment?
IDEXX Laboratories Investment Advice | IDXX |
- Examine IDEXX Laboratories' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research IDEXX Laboratories' leadership team and their track record. Good management can help IDEXX Laboratories navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact IDEXX Laboratories' business and its evolving consumer preferences.
- Compare IDEXX Laboratories' performance and market position to its competitors. Analyze how IDEXX Laboratories is positioned in terms of product offerings, innovation, and market share.
- Check if IDEXX Laboratories pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about IDEXX Laboratories' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in IDEXX Laboratories stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if IDEXX Laboratories is a good investment.
Sell | Buy |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine IDEXX Laboratories Stock
Researching IDEXX Laboratories' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 95.0% of the company shares are owned by institutional investors. The company recorded earning per share (EPS) of 10.36. IDEXX Laboratories had not issued any dividends in recent years. The entity had 2:1 split on the 16th of June 2015.
To determine if IDEXX Laboratories is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding IDEXX Laboratories' research are outlined below:
| IDEXX Laboratories generated a negative expected return over the last 90 days | |
| IDEXX Laboratories is unlikely to experience financial distress in the next 2 years | |
| IDEXX Laboratories currently holds 1.07 B in liabilities with Debt to Equity (D/E) ratio of 3.28, implying the company greatly relies on financing operations through barrowing. IDEXX Laboratories has a current ratio of 0.87, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about IDEXX Laboratories' use of debt, we should always consider it together with its cash and equity. | |
| Over 95.0% of IDEXX Laboratories shares are owned by institutional investors | |
| Latest headline from businesswire.com: IDEXX Laboratories to Release 2024 Fourth Quarter and Full Year Financial Results |
IDEXX Laboratories Quarterly Good Will |
|
IDEXX Laboratories uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in IDEXX Laboratories. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to IDEXX Laboratories' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 5th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 5th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact IDEXX Laboratories' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises IDEXX Laboratories' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2003-10-20 | 2003-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2003-04-21 | 2003-03-31 | 0.08 | 0.09 | 0.01 | 12 | ||
2002-07-15 | 2002-06-30 | 0.08 | 0.09 | 0.01 | 12 | ||
2002-04-12 | 2002-03-31 | 0.06 | 0.07 | 0.01 | 16 | ||
2001-10-15 | 2001-09-30 | 0.07 | 0.08 | 0.01 | 14 | ||
2000-04-14 | 2000-03-31 | 0.05 | 0.06 | 0.01 | 20 | ||
1998-07-17 | 1998-06-30 | 0.04 | 0.03 | -0.01 | 25 | ||
1997-10-17 | 1997-09-30 | 0.01 | 0.02 | 0.01 | 100 |
IDEXX Laboratories Target Price Consensus
IDEXX target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. IDEXX Laboratories' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 14 | Buy |
Most IDEXX analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand IDEXX stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of IDEXX Laboratories, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationIDEXX Laboratories Target Price Projection
IDEXX Laboratories' current and average target prices are 419.26 and 478.62, respectively. The current price of IDEXX Laboratories is the price at which IDEXX Laboratories is currently trading. On the other hand, IDEXX Laboratories' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
IDEXX Laboratories Market Quote on 17th of January 2025
Target Price
Analyst Consensus On IDEXX Laboratories Target Price
IDEXX Laboratories Analyst Ratings
IDEXX Laboratories' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about IDEXX Laboratories stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of IDEXX Laboratories' financials, market performance, and future outlook by experienced professionals. IDEXX Laboratories' historical ratings below, therefore, can serve as a valuable tool for investors.Know IDEXX Laboratories' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as IDEXX Laboratories is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading IDEXX Laboratories backward and forwards among themselves. IDEXX Laboratories' institutional investor refers to the entity that pools money to purchase IDEXX Laboratories' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Brown Advisory Holdings Inc | 2024-09-30 | 1.1 M | Amvescap Plc. | 2024-09-30 | 1.1 M | Norges Bank | 2024-06-30 | 994.4 K | Fundsmith Investment Services Ltd. | 2024-09-30 | 865 K | Legal & General Group Plc | 2024-09-30 | 774.7 K | Northern Trust Corp | 2024-09-30 | 769.5 K | Goldman Sachs Group Inc | 2024-09-30 | 768.6 K | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 751.9 K | Principal Financial Group Inc | 2024-09-30 | 730.5 K | Vanguard Group Inc | 2024-09-30 | 9.7 M | Blackrock Inc | 2024-09-30 | 9.4 M |
IDEXX Laboratories' market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 35.1 B.Market Cap |
|
IDEXX Laboratories' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.27 | 0.14 | |
| Return On Capital Employed | 0.43 | 0.26 | |
| Return On Assets | 0.23 | 0.24 | |
| Return On Equity | 0.65 | 0.69 |
Determining IDEXX Laboratories' profitability involves analyzing its financial statements and using various financial metrics to determine if IDEXX Laboratories is a good buy. For example, gross profit margin measures IDEXX Laboratories' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of IDEXX Laboratories' profitability and make more informed investment decisions.
IDEXX Laboratories' Earnings Breakdown by Geography
Please note, the imprecision that can be found in IDEXX Laboratories' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of IDEXX Laboratories. Check IDEXX Laboratories' Beneish M Score to see the likelihood of IDEXX Laboratories' management manipulating its earnings.
Evaluate IDEXX Laboratories' management efficiency
IDEXX Laboratories has return on total asset (ROA) of 0.2279 % which means that it generated a profit of $0.2279 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.5942 %, meaning that it created $0.5942 on every $100 dollars invested by stockholders. IDEXX Laboratories' management efficiency ratios could be used to measure how well IDEXX Laboratories manages its routine affairs as well as how well it operates its assets and liabilities. At this time, IDEXX Laboratories' Return On Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.69 in 2025, whereas Return On Tangible Assets are likely to drop 0.14 in 2025. At this time, IDEXX Laboratories' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 2.1 B in 2025, whereas Intangible Assets are likely to drop slightly above 74.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.08 | 16.89 | |
| Tangible Book Value Per Share | 11.20 | 11.76 | |
| Enterprise Value Over EBITDA | 34.53 | 19.30 | |
| Price Book Value Ratio | 35.72 | 37.50 | |
| Enterprise Value Multiple | 34.53 | 19.30 | |
| Price Fair Value | 35.72 | 37.50 | |
| Enterprise Value | 7.2 B | 7.6 B |
The management strategies employed by IDEXX Laboratories' are designed to enhance shareholder value and ensure long-term growth. We assess the effectiveness of these strategies in our stock analysis.
Beta 1.357 |
Basic technical analysis of IDEXX Stock
As of the 17th of January 2025, IDEXX Laboratories retains the Risk Adjusted Performance of (0.06), coefficient of variation of (1,325), and Market Risk Adjusted Performance of (1.62). IDEXX Laboratories technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.IDEXX Laboratories' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific IDEXX Laboratories insiders, such as employees or executives, is commonly permitted as long as it does not rely on IDEXX Laboratories' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases IDEXX Laboratories insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
IDEXX Laboratories' Outstanding Corporate Bonds
IDEXX Laboratories issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. IDEXX Laboratories uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most IDEXX bonds can be classified according to their maturity, which is the date when IDEXX Laboratories has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| International Game Technology Corp BondUS460599AD57 | View | |
| IEX 2625 15 JUN 31 Corp BondUS45167RAH75 | View | |
| US45167RAG92 Corp BondUS45167RAG92 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand IDEXX Laboratories' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing IDEXX Laboratories' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (1.62) | |||
| Mean Deviation | 1.23 | |||
| Coefficient Of Variation | (1,325) | |||
| Standard Deviation | 1.88 | |||
| Variance | 3.53 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.14) | |||
| Treynor Ratio | (1.63) | |||
| Maximum Drawdown | 11.58 | |||
| Value At Risk | (2.63) | |||
| Potential Upside | 2.55 | |||
| Skewness | (2.00) | |||
| Kurtosis | 9.89 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (1.62) | |||
| Mean Deviation | 1.23 | |||
| Coefficient Of Variation | (1,325) | |||
| Standard Deviation | 1.88 | |||
| Variance | 3.53 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.15) | |||
| Total Risk Alpha | (0.14) | |||
| Treynor Ratio | (1.63) | |||
| Maximum Drawdown | 11.58 | |||
| Value At Risk | (2.63) | |||
| Potential Upside | 2.55 | |||
| Skewness | (2.00) | |||
| Kurtosis | 9.89 |
Consider IDEXX Laboratories' intraday indicators
IDEXX Laboratories intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of IDEXX Laboratories stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 25859.3 | |||
| Daily Balance Of Power | (0.67) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 425.94 | |||
| Day Typical Price | 423.71 | |||
| Price Action Indicator | (11.36) | |||
| Period Momentum Indicator | (9.36) |
IDEXX Laboratories Corporate Filings
8K | 12th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 29th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 4th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 31st of May 2024 Other Reports | ViewVerify |
IDEXX Stock media impact
Far too much social signal, news, headlines, and media speculation about IDEXX Laboratories that are available to investors today. That information is available publicly through IDEXX media outlets and privately through word of mouth or via IDEXX internal channels. However, regardless of the origin, that massive amount of IDEXX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of IDEXX Laboratories news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of IDEXX Laboratories relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to IDEXX Laboratories' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive IDEXX Laboratories alpha.
IDEXX Laboratories Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards IDEXX Laboratories can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Idexx Sees Q3 Revenue Boost
recently @ www.fool.com
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
IDEXX Laboratories Maximum Pain Price Across April 17th 2025 Option Contracts
IDEXX Laboratories' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of IDEXX Laboratories close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of IDEXX Laboratories' options.
IDEXX Laboratories Corporate Management
| Sharon JD | General VP | Profile | |
| Nimrata PE | Executive Commercial | Profile | |
| Julie Godon | Senior Officer | Profile | |
| Jeffery Chadbourne | Director Reporting | Profile | |
| George Fennell | Senior Officer | Profile |
Additional Tools for IDEXX Stock Analysis
When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.